Eledon Pharmaceuticals (ELDN) closed at $2.37 on November 12, 2026, down 11.4% from the previous close, on volume of 771,607 shares (30-day average 837,676).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Eledon Pharmaceuticals GAAP EPS of -$0.03 beats by $0.14
Seeking Alpha News (Fri, 13-Nov 1:20 PM ET)
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 12-Nov 4:35 PM ET)
NewcelX prices $1.55M share offering at $3.29 to fund diabetes program
Seeking Alpha News (Mon, 9-Nov 10:09 AM ET)
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Globe Newswire (Mon, 5-Oct 4:05 PM ET)
Market Chameleon (Tue, 22-Sep 7:37 AM ET)
Globe Newswire (Tue, 22-Sep 7:00 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Globe Newswire (Thu, 3-Sep 7:00 AM ET)
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Eledon Pharmaceuticals trades on the NASDAQ stock market under the symbol ELDN.
As of November 13, 2026, ELDN stock price declined to $2.12 with 1,076,490 million shares trading.
ELDN has a beta of 3.27, meaning it tends to be more sensitive to market movements. ELDN has a correlation of 0.13 to the broad based SPY ETF.
ELDN has a market cap of $172.27 million. This is considered a Micro Cap stock.
In the last 3 years, ELDN traded as high as $5.54 and as low as $1.11.
The top ETF exchange traded funds that ELDN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ELDN has outperformed the market in the last year with a return of +12.2%, while the SPY ETF gained +11.3%. However, in the most recent history, ELDN shares have underperformed the stock market with its stock returning -43.8% in the last 3 month period and -30.3% for the last 2 week period, while SPY has returned -2.3% and -2.2%, respectively.
ELDN support price is $2.22 and resistance is $2.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELDN shares will trade within this expected range on the day.
